Abingworth raises $356m for new CCD fundRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes. more ➔
TCMStudy links TCM with effects on protein networksBy mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms. more ➔
Cancer vaccinesBioNtech reports Car-T/mRNA booster study results at ESMOBioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid more ➔
M&ARoche acquires Telavant Holdings to win TLA1 raceAnalysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings. more ➔
AMRUK boosts AMR defenses with £30m PACE initiativeIn an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical … more ➔
CPHI: Trends shaping pharma’s pathThis week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships. more ➔
FinancingXlife Sciences AG acquires 20% stake in 4D Lifetec AGIn a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an … more ➔
CollaborationSpliceBio has made up a US $216m alliance with Spark TherapeuticsSpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease. more ➔
CollaborationAntiverse and GlobalBio Inc. extend collaborationAntiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development more ➔
ADCSOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BVSotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates. more ➔
